Clinical TrialMay 12, 2026, 09:33 AM
Geron RYTELO Real-World Study Shows 37.5% RBC-TI in LR-MDS Patients
AI Summary
Geron Corporation announced positive real-world evidence for RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS), with data to be presented at the European Hematology Association (EHA) 2026 Congress. The investigator-sponsored study at Moffitt Cancer Center demonstrated safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population. The study reported a 37.5% red blood cell transfusion independence rate lasting at least eight weeks in heavily pretreated LR-MDS patients. Geron will also present additional data on its myelofibrosis and AML clinical programs at EHA 2026 and ASCO 2026.
Key Highlights
- Real-world study of RYTELO in LR-MDS showed 37.5% red blood cell transfusion independence (>8 weeks).
- Study included 40 heavily transfusion-dependent LR-MDS patients with extensive prior therapies.
- Safety and efficacy were generally consistent with findings from the Phase 3 IMerge trial.
- Cytopenias were reported as the most common Grade 3/4 adverse event.
- Exploratory analyses suggested improved responses when RYTELO was used within the first three lines of therapy.
- Geron will have additional presentations at EHA 2026 and ASCO 2026 on myelofibrosis and AML programs.
Price Impact
More from GERN
More in Clinical Trial